Cargando…

Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib

BACKGROUND: Sunitinib prolonged progression-free survival (PFS) versus placebo in patients with metastatic pancreatic neuroendocrine tumors (panNETs) in a phase III trial. The efficacy and safety of sunitinib in patients with panNETs were confirmed in an open-label phase IV trial. OBJECTIVE: To asse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fazio, Nicola, Kulke, Matthew, Rosbrook, Brad, Fernandez, Kathrine, Raymond, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810649/ https://www.ncbi.nlm.nih.gov/pubmed/33411058 http://dx.doi.org/10.1007/s11523-020-00784-0

Ejemplares similares

Safety and Efficacy of Sunitinib in Patients with Unresectable Pancreatic Neuroendocrine Tumors
por: Wiedmann, Marcus W., et al.
Publicado: (2012)

Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib
por: Jiménez-Fonseca, Paula, et al.
Publicado: (2018)

Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response
por: Lamarca, Angela, et al.
Publicado: (2018)

Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor
por: Valdes-Socin, Hernan, et al.
Publicado: (2017)

Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
por: Ito, Tetsuhide, et al.
Publicado: (2013)

Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study
por: Ito, Tetsuhide, et al.
Publicado: (2019)

Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours
por: Zurita, A J, et al.
Publicado: (2015)

Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
por: Signorovitch, James, et al.
Publicado: (2013)

Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms
por: Murase, Yoshiki, et al.
Publicado: (2021)

Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
por: Solis-Hernandez, Mª Pilar, et al.
Publicado: (2019)

Transformation of Nonfunctioning Pancreatic Neuroendocrine Carcinoma Cells into Insulin Producing Cells after Treatment with Sunitinib
por: Ohn, Jung Hun, et al.
Publicado: (2013)

Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms
por: Daskalakis, Kosmas, et al.
Publicado: (2019)

Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine Tumors
por: Kulke, Matthew H, et al.
Publicado: (2011)

Everolimus in advanced, progressive, well‐differentiated, non‐functional neuroendocrine tumors: RADIANT‐4 lung subgroup analysis
por: Fazio, Nicola, et al.
Publicado: (2017)

Two well-differentiated pancreatic neuroendocrine tumor mouse models
por: Wong, Chung, et al.
Publicado: (2019)

Current update on imaging for pancreatic neuroendocrine neoplasms
por: Segaran, Nicole, et al.
Publicado: (2021)

Optimal Lymphadenectomy in Patients with Well-Differentiated Nonfunctioning Pancreatic Neuroendocrine Neoplasms
por: Shintakuya, Ryuta, et al.
Publicado: (2023)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer
por: Powles, Thomas, et al.
Publicado: (2008)

Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

A Case of Metastatic Adamantinoma That Responded Well to Sunitinib
por: Liman, Andrew D., et al.
Publicado: (2016)

Effect of Endostar combined with chemotherapy in advanced well-differentiated pancreatic neuroendocrine tumors
por: Cheng, Yue-Juan, et al.
Publicado: (2018)

Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor
por: Williamson, Laura M., et al.
Publicado: (2019)

Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study
por: Sato, Kazuo, et al.
Publicado: (2018)

The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer
por: Martínez-Bosch, Neus, et al.
Publicado: (2016)

Targeting the mTOR Signaling Pathway in Neuroendocrine Tumors
por: Chan, Jennifer, et al.
Publicado: (2014)

Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors
por: Tan, Qing-quan, et al.
Publicado: (2020)

An Overview of Pancreatic Neuroendocrine Tumors and an Update on Endoscopic Techniques for Their Management
por: Elkelany, Osama O., et al.
Publicado: (2023)

Simultaneous Resection of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases: Safety and Oncological Efficacy
por: Addeo, Pietro, et al.
Publicado: (2022)

Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience
por: Hwang, Eugene, et al.
Publicado: (2010)

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer
por: Powles, T., et al.
Publicado: (2011)

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
por: Rini, Brian I., et al.
Publicado: (2011)

Somatic VHL Mutation in a Patient With MEN1-Associated Metastatic Pancreatic Neuroendocrine Tumor Responding to Sunitinib Treatment: A Case Report
por: Shell, Jasmine, et al.
Publicado: (2017)

Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review
por: Bocchini, Martine, et al.
Publicado: (2020)

Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma
por: Zhu, Xudong, et al.
Publicado: (2021)

Primary Well-Differentiated Neuroendocrine Tumor of the Kidney
por: Prasad, Vishnu, et al.
Publicado: (2023)

Sunitinib Potentiates the Cytotoxic Effect of Electrochemotherapy in Pancreatic Carcinoma Cells
por: Bosnjak, Masa, et al.
Publicado: (2022)

Clinical and Molecular Risk Factors for Recurrence Following Radical Surgery of Well-Differentiated Pancreatic Neuroendocrine Tumors
por: Pulvirenti, Alessandra, et al.
Publicado: (2020)

Values of debulking surgery for unresectable well-differentiated metastatic pancreatic neuroendocrine tumors: a comparative study
por: Huang, Xi-Tai, et al.
Publicado: (2023)

Targeted deep sequencing reveals the genetic heterogeneity in well-differentiated pancreatic neuroendocrine tumors with liver metastasis
por: Zhou, Wentao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_54d8v9ceugg5h01g83s9rv89ou